サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：扁平上皮癌の世界市場-2022-2029年
市場調査レポート
商品コード
1129239

扁平上皮癌の世界市場-2022-2029年

Global Cutaneous Squamous Cell Carcinoma Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
扁平上皮癌の世界市場-2022-2029年
出版日: 2022年09月29日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

扁平上皮癌の非侵襲的な診断技術の増加が市場成長の原動力になると予想されます。

進行したcSCCの診断には、皮膚科医、解剖病理医、外科医、放射線腫瘍医、腫瘍内科医など、異なる専門分野の専門家が関与するため、より包括的な患者評価が可能になります。非侵襲的な光学診断技術は、診断精度を高め、手術や生検の前に生体内で腫瘍の特徴を把握するために、臨床の場でますます使用されるようになってきています。クラスター化した血管パターン、糸球体血管、過角化などのcSCCの主要な特徴は、ダーモスコピーで確認することができます。反射型共焦点顕微鏡では、表皮の有棘顆粒層における異常なハニカムパターンや無秩序なパターン、表皮の丸い有核輝細胞、丸い真皮静脈のモノを確認できます。さらに、ダーモスコピーは、不明瞭な症例の鑑別診断において、非色素性病変よりも色素性病変でよく使用されます。したがって、上記の記述から、市場の成長を促進することが期待されます。

制約事項

治療費の高騰、治療費の償還不足、合併症の増加、疾患の早期発見の欠如などが、予測期間中に市場が阻害される要因であると考えられています。

産業分析

扁平上皮癌市場は、ポーターの5力、サプライチェーン分析、償還シナリオ、パイプライン分析、製品イノベーション、価格分析など、さまざまな業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19の大流行は、ヘルスケアシステムと市場に中程度の影響を及ぼしています。流行している病気に対する医療・外科手術は、封鎖のために遅れています。さらに、COVIDに感染していない患者は、緊急でない医療機関の受診がキャンセルまたは延期され、人々はウイルスに感染してシステムにさらに負担をかけることを恐れて、医療サービスに連絡することをためらっています。その結果、世界的にがんの診断が減少し、特に皮膚の悪性腫瘍の診断が減少しています。例えば、オランダの研究では、2020年2月末から4月初めにかけて、1週間のがん診断数が全悪性腫瘍で最大27％、皮膚がんで61％減少したことが分かっています。

さらに、パンデミックはサプライチェーンやプロセスに支障をきたします。多くの企業は、製品の入手可能性を確保し、サプライチェーンを保護するために、他の地域へと変化していくでしょう。したがって、上記の記述から、市場は影響を受けたが、経済活動の再開に伴い、迅速に牽引力を得ることが期待されます。

世界の扁平上皮癌市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場インパクトファクター
    • 促進要因
      • 扁平上皮癌の非侵襲的診断技術の増加が市場成長を促進すると予想されます。
    • 抑制要因
      • 治療費の高騰が予測期間中の阻害要因となる見込みです。
    • 機会
    • 影響分析

第5章 産業分析

  • サプライチェーン分析
  • 価格設定分析
  • アンメットニーズ分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 診断分野別

  • CT
  • MRI
  • 生検
  • その他

第8章 治療タイプ別

  • 外科的治療
    • モースマイクログラフィックサージェリー（MMS）
    • 掻爬・電極焼灼術
    • 切除手術
    • クライオサージェリー
    • レーザー手術
    • その他
  • 非外科的治療
    • 免疫応答改善剤（外用
      • イミキモド
      • レジキモド
    • 化学療法
    • 薬物療法
      • キイトルーダ（ペムブロリズマブ）
      • リブタイヨ（セミプロリマブ）
      • その他
    • 放射線療法
    • 光線力学的療法（PDT）
    • 全身化学療法
    • その他
  • その他

第9章 治療法別売上高

  • エンドユーザー
    • 病院
    • 外来手術センター
    • 診断センター
    • その他
  • 販売チャネル
    • 病院内薬局
    • 小売薬局
    • オンライン薬局
    • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • Regeneron Pharmaceuticals, Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Sanofi
  • Merck & Co., Inc.
  • Mayne Pharma Group Limited
  • iNova Pharmaceuticals
  • Bristol-Myers Squibb Company
  • LGM PHARMA
  • Hikma Pharmaceuticals PLC
  • 3M Health Care Limited

第13章 扁平上皮癌の世界市場-DataM

目次
Product Code: DMPH5778

Market Overview

Cutaneous Squamous Cell Carcinoma Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 7.2 % during the forecast period (2022-2029).

Cancer starts in the cells that make up the epidermis (the outer layer of the skin). It commonly develops in parts of the skin that have been exposed to long periods of natural or artificial sunlight (such as from tanning beds). The face, ears, lower lip, neck, arms, and backs of the hands are examples of these locations. It can also happen if you've had your skin burned or exposed to chemicals or radiation. A hard red bump, a scaly red patch, an open sore, or a wart that crusts or bleeds easily can all be signs of cutaneous squamous cell carcinoma. Squamous cell carcinoma of the skin that hasn't spread can typically be cured.

Market Dynamics

Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.

Diagnosis of advanced cSCC involves experts from different specialties, including dermatologists, anatomical pathologists, surgeons, radiation oncologists, and medical oncologists, thereby enabling a more comprehensive patient assessment. Noninvasive optical diagnostic techniques are increasingly used in clinical practice to increase diagnostic accuracy and characterize tumors in vivo before surgery or biopsy. The primary characteristics of cSCC, such as clustered vascular patterns, glomerular vessels, and hyperkeratosis, can be identified through dermoscopy. Reflectance confocal microscopy can reveal aberrant honeycomb or disorganized patterns in the epidermis' spinous-granular layer, round nucleated brilliant cells in the epidermis, and round dermis veins things. Moreover, dermoscopy is used more commonly in pigmented lesions than in non-pigmented lesions in the differential diagnosis of equivocal cases. Thus, from the above statements, the market is expected to drive market growth.

Restraint:

The high cost of the treatment, lack of reimbursement for the treatment, increase in complications rate, and lack of early detection of the diseases are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cutaneous squamous cell carcinoma market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, pipeline analysis, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Medical and surgical operations for prevalent ailments have been delayed due to the lockdown. Moreover, Non-COVID patients had non-urgent medical visits canceled or postponed, and people were hesitant to contact healthcare services for fear of getting the virus and burdening the system further. This has resulted in a decrease in cancer diagnoses worldwide, particularly in skin malignancies. For instance, a Dutch study found a decline in weekly cancer diagnoses of up to 27% for all malignancies and 61% for skin cancers between the end of February and the beginning of April 2020.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Surgical segment is expected to hold the largest market share in cutaneous squamous cell carcinoma market

The surgical segment is expected to dominate in 2021. Most squamous cell carcinomas of the skin can be eliminated with minimal surgery or, on rare occasions, with a topical medication. The size, location, and aggressiveness of the tumor matter. For instance, Based on excellent cure rates and low recurrence rates reported in retrospective assessments of initial and recurrent cSCC, Mohs micrographic surgery (MMS) might be the best approach for high-risk patients. Moreover, if skin cancer is very small and has a low risk of spreading, less invasive treatments are the treatment choice. For instance, Curettage and electrodessication (C and E) treatment involves removing the skin cancer surface with a scraping instrument (curet) and then searing the base of the cancer with an electric needle. This treatment is often used for small or very superficial squamous cell skin cancers. Therefore, there is an increase in the demand for surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global cutaneous squamous cell carcinoma market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cutaneous squamous cell carcinoma, advancements in the treatment, well-established infrastructure and product launches and collaborations by the key players are some factors the market is expected to boost in the forecast period. For instance, Cutaneous squamous cell carcinoma (CSCC, also called squamous cell carcinoma of the skin) is the second most common form of skin cancer and five times more prevalent than melanoma in the U.S. Moreover, according to the American Cancer Society, Of nonmelanoma skin cancers, approximately 80% are basal cell carcinoma (BCC), and 20% are squamous cell carcinoma (SCC). In addition, Regeneron Pharmaceuticals, Inc. announced its intention to buy Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab) on June 2, 2022 giving Regeneron exclusive global development, commercialization, and manufacturing rights to the medicine.

Furthermore, Merck & Co., Inc. received FDA approval for pembrolizumab (KEYTRUDA) in June 2020. The drug is approved to treat recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) resistant to surgery or radiation. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the cutaneous squamous cell carcinoma market are Regeneron Pharmaceuticals, Inc., Sanofi, Merck & Co., Inc., Mayne Pharma Group Limited, iNova Pharmaceuticals, Bristol-Myers Squibb Company, LGM PHARMA, Hikma Pharmaceuticals PLC, 3M Health Care Limited

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology business based in New York's Westchester County. The business was established in 1988. The company began by studying neurotrophic factors, and their regenerative abilities, hence its name, and subsequently expanded to include cytokine and tyrosine kinase receptor research. Currently, the company engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

LIBTAYO (cemiplimab-rwlc) injection: LIBTAYO is indicated for treating patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

The global cutaneous squamous cell carcinoma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high costs of treatment are expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 7.2. CT
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. MRI
  • 7.4. Biopsy
  • 7.5. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Surgical*
    • 8.2.1. Moh's Micrographic Surgery (MMS)
    • 8.2.2. Curettage and electrodesiccation
    • 8.2.3. Excisional surgery
    • 8.2.4. Cryosurgery
    • 8.2.5. Laser surgery
    • 8.2.6. Others
    • 8.2.7. Introduction
    • 8.2.8. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Non-surgical
    • 8.3.1. Topical Immune Response Modifiers
      • 8.3.1.1 Imiquimod
      • 8.3.2.1Resiquimod
    • 8.3.2. Chemotherapy
    • 8.3.3. Medications
      • 8.3.3.1 Keytruda (Pembrolizumab)
      • 8.3.3.2 Libtayo (Cemiplimab-rwlc)
      • 8.3.3.3 Others
    • 8.3.4. Radiotherapy
    • 8.3.5. Photodynamic therapy (PDT)
    • 8.3.6. Systemic Chemotherapy
    • 8.3.7. Others
  • 8.4. Others

9. By Treatment Sales

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 9.1.2. Market Attractiveness Index, By Treatment Sales Segment
  • 9.2. End user*
    • 9.2.1. Hospitals
    • 9.2.2. Ambulatory Surgical Center
    • 9.2.3. Diagnostic Centers
    • 9.2.4. Others
    • 9.2.5. Introduction
    • 9.2.6. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Regeneron Pharmaceuticals, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi
  • 12.3. Merck & Co., Inc.
  • 12.4. Mayne Pharma Group Limited
  • 12.5. iNova Pharmaceuticals
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. LGM PHARMA
  • 12.8. Hikma Pharmaceuticals PLC
  • 12.9. 3M Health Care Limited

LIST NOT EXHAUSTIVE

13. Global Cutaneous Squamous Cell Carcinoma Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us